Background
In Italy, about 600,000 patients are affected by ulcers of neuro-vascular origin, 50% of which are represented by venous chronic ulcers, inveterate and painful. (Surveying of the Ministry of Health -2001) . Of these approximately 60% are constituted by elderly patients.
Objective
To verify the results obtained in 240 elderly patients, age ranged between 70 and 92 years-old (66.9% females -31.1% males), affected with ulcers of the lower limbs, treated by cultivated autografts of skin, from April 2001 to August 2008.
Materials and methods
The biotechnologies are based on the drawing of a small fragment of skin (2-3 cmq), at the elbow. Subsequently, the skin fragment is sent to a specialized laboratory in cellular cultivated membrane, where it is divided into its two essential components: dermatocytes and cheratinocytes. These, after having been separated, centrifugated and implanted on an adapted medium which consists of modified three-dimensional jaluronic acid, develop in vitro an extended layer of tissue (dimensions 100-200 cmq), which then will be grafted separately (after 4 weeks from the biopsy) on the surface of the ulcer.
For the correct execution of such procedure are necessary four surgical steps, in sequence:
1. The debridement of the ulcer, the elasto-compressive bendage of the leg and the drawing of the skin.
2. The grafting of the layer of dermatocytes (called Hyalograft 3D) after 22-30 days.
3. The grafting of the layer of cheratinocytes (called Laserskin), after others 22-30 days.
4. The surgical treatment of the venous or arterial insufficiency after 1-10 months.
Results
We have performed a total of 520 autografts (234 dermatocytes -286 cheratinocytes). Approximately half of the ulcers treated, were venous chronic ulcers, inveterate and painful secondary to chronic venous insufficiency of the lower limbs and/or post-thrombotic syndrome.
A clinical follow-up was performed on 186 out of the 240 cases, medially for 26 months (ranging between 3 months -7 years and 4 months). In reference our experience, on the 240 cases treated, we have obtained 207 cases (86.25%) of complete healing, 27 cases (11.25%) of partial healing, with a reduction of the ulcerated area >50%, 6 cases (2.5%) of therapeutic failure, with a reduction of the ulcerated area <50%, 2 cases (0.83%) of amputations and 18 cases (7.5%) of relapses. The mean time for the complete closing of the ulcers has been of 13.4 weeks calculated by the date of the first graft (range 4.1-33.2 weeks). Data on line to the more recent literature, in which is described a percentage of 95% of good clinical results (ulcers partially and completely closed) and stable in the time.
